Trial · NCT06222801
The 1st Tumor CytokinoTherapy Database (TCTD-1)
NCT06222801, Recruiting, OncoCareClinic 308 Ltd
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The 1st Tumor CytokinoTherapy Database (TCTD-1). Trials, record NCT06222801. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06222801
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The 1st Tumor CytokinoTherapy Database (TCTD-1)
- NCT number
- NCT06222801
- Status
- Recruiting
- Enrollment
- 5,000 participants, estimated
- Lead sponsor
- OncoCareClinic 308 Ltd
- Conditions
- Oncology
- Interventions
- Tumor necrosis factor alpha, Interferon gamma
- First posted
- 2024-01-25
- Last updated
- 2024-06-10
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate | 10 years | Number of objective responses to therapy before progression or relapse. |
| Secondary | Changes in functional status since the start of cytokinegenetic therapy during treatment and observation. | 10 years | The Karnofsky index parameter will be evaluated. |
| Secondary | Overall survival of patients since the start of cytokinogenetic therapy. | 10 years | The time elapsed between the start of cytogenetic therapy and the death of the patient (for any reason, including those not related to oncology). |
| Secondary | Relapse-free survival of patients since the start of cytokinogenetic therapy. | 10 years | The time elapsed between the start of cytokinogenetic therapy and the detection of relapse or death of the patient (for any reason, including those not related to oncology). |
| Secondary | The appearance of toxicity from the moment of initiation of cytokinogenetic therapy. | 10 years | AEs associated with cytokine therapy. |
| Secondary | Changes in the level of TNF in the blood since the start of cytokinegenetic therapy during treatment and observation. | 10 years | Dynamics of TNF levels in the blood throughout the study. |
| Secondary | Duration of response to cytokinogenetic therapy. | 10 years | Duration of response to therapy as time to event (progression or relapse). Analysis of duration of response will be performed in the group of patients who responded to therapy. |
| Secondary | Disease control rate. | 10 years | The number of patients who achieve disease control will be assessed every 3 months until progression or relapse occurs. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06222801
GET https://conductscience.org/api/trials/v1/NCT06222801/registered